News & Updates
Filter by Specialty:
Real-world data back CV safety of JAK inhibitors
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
Real-world data back CV safety of JAK inhibitors
28 Jun 2023
SGLT2 inhibitors score big, this time in gout
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
SGLT2 inhibitors score big, this time in gout
22 Jun 2023
Novel drug STRIDES in the right direction for knee OA
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).
Novel drug STRIDES in the right direction for knee OA
21 Jun 2023
AI predicts early-stage rheumatoid arthritis using MRI scans
It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.